AusBiotech makes submission on R&D Tax Incentive quarterly payments
13 September, 2012 by AusBiotechAusBiotech has been advocating for quarterly payments since its first submission on the Tax Credit and is pleased to see the Government responsive to the cash-flow needs of small companies, giving companies the ability to smooth out cash-flow over the year and provide increased predictability.
Phylogica looks to recoup $1.9m from R&D Tax Incentive
13 September, 2012 by Dylan Bushell-EmblingThe first wave of companies is beginning to take advantage of the government’s recently installed R&D Tax Incentive, with Phylogica (ASX:PYC) lodging an application to recoup $1.9 million in research and development costs.
Bioniche FY12 loss doubles to $24m
13 September, 2012 by Dylan Bushell-EmblingBioniche (ASX:BNC) said its net loss for FY12 nearly doubled to C$24.1 million ($23.6 million), even as revenue from its animal health division grew by over 10%.
Phylogica wins cosmetics deal for peptides
12 September, 2012 by Dylan Bushell-EmblingPhylogica (ASX:PYC) is continuing its push into the cosmetics market with a deal to license a phylomer peptide with skin repair potential to US-based luxury beauty product company Le Métier de Beauté.
CSL wins flu vaccine contract in US
12 September, 2012 by Dylan Bushell-EmblingCSL (ASX:CSL) subsidiary CSL Biotherapies has won a flu vaccine contract with the US health department that could be worth as much as US$1.5 billion in the event of a pandemic.
Highly-specialised BD course with subsidy for approved Victorian companies
11 September, 2012 by AusBiotechGlobal business development (BD) ‘guru,’ Jack Anthony, will visit the AusBiotech 2012 national conference to run a not-to-be-missed professional development course for BD professionals: ‘The Secret Sauce of Deal Making’.
Bacteriophage companies AmpliPhi and SPH to merge
11 September, 2012 by Dylan Bushell-EmblingUS-based AmpliPhi Biosciences and Australia's Special Phage Holdings (SPH) have revealed plans to merge to create a global bacteriophage-based therapy company.
Patrys closes $2.85m capital raising
10 September, 2012 by Dylan Bushell-EmblingPatrys (ASX:PAB) has completed the share purchase plan component of a capital raising worth $2.85 million. The clinical stage biopharmaceutical company fell just shy of hitting the maximum target for the capital raising of $2.9 million.
CBio now Invion after completing merger
07 September, 2012 by Dylan Bushell-EmblingAustralian drug developer CBio has completed its merger with US-based Inverseon and formally changed its name to Invion (ASX:IVX).
AstraZeneca evaluating Starpharma cancer drugs
07 September, 2012 by Dylan Bushell-EmblingStarpharma's (ASX:SPL) cancer drug development platform has attracted the attention of UK pharmaceutical giant AstraZeneca.
FDA decision on MoxDuo expected mid-2013
06 September, 2012 by Dylan Bushell-EmblingAfter being cleared to submit existing trial data to back up its IND application for pain formulation MoxDuo IR, QRxPharma (ASX:QRX) now expects the US FDA to make its decision in mid-2013.
Iluvien may get UK NHS listing
06 September, 2012 by Dylan Bushell-EmblingpSivida (ASX:PVA) licensee Alimera has scored a win in efforts to gain UK acceptance for the Iluvien micro-insert as a treatment for chronic diabetic macular edema (DME).
AusBiotech announces 2012 AGM and Board elections
06 September, 2012 by AusBiotechAusBiotech has announced it will hold its annual general meeting at the AusBiotech 2012 national conference in Melbourne on Thursday 1 November 2012 at 1:00pm, where business will include the outcome of the election for two directors to join the AusBiotech Board.
NSW kicks off medical devices fund
06 September, 2012 by Dylan Bushell-EmblingThe NSW government has launched a seven-figure fund to encourage the development and commercialisation of innovative medical devices in the state.
Avita launches capital raising for spray-on skin
05 September, 2012 by Dylan Bushell-EmblingAvita Medical (ASX:AVH) will raise up to $10m through a placement and SPP to support marketing and US commercialisation efforts for its ReCell Spray-On Skin technology.
